Abstract
Gangliosides GD3 and GD2 are specifically expressed in neuro-ectoderm-derived tumors, and are considered to play roles in the malignant properties of those cells. We analysed effects of small interfering (si) RNAs against GD3 synthase gene on the expression of ganglioside GD2 and biological phenotypes of human lung cancer cells expressing GD2. An siRNA could suppress the mRNA level of GD3 synthase gene even by single transfection, whereas repeated transfection was required to suppress GD2 expression on the cell surface. Significant reduction in the cell growth and invasion activity was observed in both lung cancer cell lines examined, when repeatedly transfected with the siRNA twice a week. DNA ladder formation was observed after third transfection, indicating the potent induction of apoptosis. Stable transfection of an RNAi expression vector with H1 RNA promoter was also examined. Transfectant cells with the RNAi expression vector showed almost equivalent suppression of GD2 expression and tumor properties in vitro. Furthermore, the stable transfectant cells showed slower cell growth than the control cells in severe combined immunodeficiency mice. These results suggested that siRNAs and/or RNAi expression vectors to generate siRNAs are promising approach to overcome human lung cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S et al. (2005). J Biol Chem 80: 29828–29836.
Aoki H, Satoh M, Mitsuzuka K, Ito A, Saito S, Funato T et al. (2004). FEBS Lett 567: 203–208.
Bai X, Zhou D, Brown JR, Crawford BE, Hennet T, Esko JD . (2001). J Biol Chem 276: 48189–48195.
Barik S . (2004). Ann Med 36: 540–551.
Brummelkamp TR, Bernards R, Agami R . (2002). Science 296: 550–553.
Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM . (1984). Biochem Biophys Res Commun 120: 500–504.
Damstrup L, Voldborg BR, Span-Thomser M, Brünner N, Poulsen HS . (1998). Br J Cancer 78: 631–640.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . (2001). Nature 411: 494–498.
Fenderson BA, Eddy EM, Hakomori S . (1990). Bioessays 12: 173–179.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC . (1998). Nature 391: 806–811.
Fukumoto S, Mutoh T, Hasegawa T, Miyazaki H, Okada M, Goto G et al. (2000). J Biol Chem 275: 5832–5838.
Furukawa K, Arita Y, Satomi N, Eisinger M, Lloyd KO . (1990). Arch Biochem Biophys 281: 70–75.
Hakomori S . (1990). J Biol Chem 265: 18713–18716.
Hakomori S . (2002). Proc Natl Acad Sci USA 99: 10231–10233.
Hamamura K, Furukawa K, Hayashi T, Hattori T, Nakano J, Nakashima H et al. (2005). Proc Natl Acad Sci USA 102: 11041–11046.
Haraguchi M, Yamashiro S, Yamamoto A, Furukawa K, Takamiya K, Lloyd KO et al. (1994). Proc Natl Acad Sci USA 91: 10455–10459.
Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD . (2002). EMBO J 21: 6289–6302.
Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S et al. (1985). Proc Natl Acad Sci USA 82: 1242–1246.
Izquierdo M . (2005). Cancer Gene Ther 12: 217–227.
Kojima Y, Fukumoto S, Furukawa K, Okajima T, Wiels J, Yokoyama K et al. (2000). J Biol Chem 275: 15152–15156.
Okada M, Furukawa K, Yamashiro S, Yamada Y, Haraguchi M, Horibe K et al. (1996). Cancer Res 56: 2844–2848.
Portoukalian J, Zwingelstein G, Dore JF . (1979). Eur J Biochem 94: 19–23.
Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ . (1982). J Exp Med 155: 1133–1147.
Schengrund CL . (1990). Brain Res Bull 24: 131–141.
Scherer L, Rossi JJ . (2004). Curr Pharm Biotechnol 5: 355–360.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada T, Harano T et al. (2004). Cancer Res 64: 3753–3760.
Waterhouse PM, Wang MB, Lough T . (2001). Nature 411: 834–842.
Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K . (2001). Cancer Res 61: 4244–4252.
Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS . (1988). J Neurochem 50: 1825–1829.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ko, K., Furukawa, K., Takahashi, T. et al. Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene 25, 6924–6935 (2006). https://doi.org/10.1038/sj.onc.1209683
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209683
Keywords
This article is cited by
-
Signaling domains of cancer-associated glycolipids
Glycoconjugate Journal (2022)
-
Sialylation: an Avenue to Target Cancer Cells
Pathology & Oncology Research (2016)
-
Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer
Journal of Cancer Research and Clinical Oncology (2009)
-
Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference
Pathology & Oncology Research (2007)